Prevymis (letermovir) - Merck (MSD)
Letermovir in ART-treated HIV-infected Persons (clinicaltrials.gov) - Jul 15, 2025 - P=N/A | N=33 | Completed | Sponsor: Jean-Pierre Routy | Active, not recruiting ➔ Completed | N=60 ➔ 33 | Trial completion date: Dec 2025 ➔ Jul 2025 
Enrollment change • Trial completion • Trial completion date • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Inflammatory Bowel Disease • CD4
http://clinicaltrials.gov/ct2/show/NCT05362916
 
Jul 15, 2025
 
Prev Next